查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835349

影像導引治療系統市場（按顯像模式、應用、最終用戶、產品、組件和治療類型）—全球預測 2025-2032

Image-guided Therapy System Market by Imaging Modality, Application, End User, Product, Component, Therapy Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，影像導引治療系統市場將成長至 85.4 億美元，複合年成長率為 7.49%。

主要市場統計數據
預測年份（2024年） 47.9億美元
基準年（2025年） 51.4億美元
預測年份（2032年） 85.4億美元
複合年成長率（%） 7.49%

全面介紹不斷發展的影像導引治療領域，其中臨床精準度、整合平台和價值主導採購正在重新定義採用模式

影像引導治療領域正處於曲折點，臨床需求、技術成熟度以及支付方和醫療服務提供者的期望正在匯聚，要求更快、更安全、更具成本效益的治療。醫院和專科中心正在從基於點的影像處理硬體投資轉向整合解決方案，將先進的顯像模式、即時導航和軟體主導的工作流程控制融為一體。這種轉變的驅動力在於：臨床醫生對提高手術精準度的需求，管理人員對吞吐量和可預測結果的關注，以及患者對創傷較小的治療途徑的期望。

臨床上，增強可視化和導航的優勢顯而易見：縮短手術時間，最大限度地減少某些治療方式的輻射暴露，並提高複雜解剖結構的靶向精度。在營運方面，混合套件和可互通平台的推動正在改變採購週期。資本負責人現在不僅會評估系統的影像質量，還會考慮軟體的擴充性、服務包以及與現有手術室生態系統投資的兼容性。因此，臨床、採購和IT部門的相關人員擴大參與技術評估和採用決策。

監管監督和報銷動態正在塑造技術應用的速度和性質。監管機構更重視上市後證據和實際應用效果，尤其是對於整合機器學習和自主功能的系統。同時，付款人和醫療系統也越來越注重基於價值的治療結果，要求供應商證明新技術如何減少併發症、縮短住院時間並改善後續護理路徑。這些因素共同凸顯了供應商需要展示可靠的臨床證據、清晰的營運優勢和靈活的商業模式，以確保其在各種醫療環境中得到廣泛應用。

分析影響影像導引治療系統和臨床應用未來的關鍵技術、營運和供應鏈轉型

影像引導治療領域正在經歷一場變革性的轉變，這受到多種技術和市場動態的共同驅動。人工智慧和機器學習的進步正在改善影像重建、分割和決策支援，使臨床醫生能夠更快、更一致地解讀多模態影像輸入。機器人技術和增強型導航系統正與影像處理設備更加緊密地整合，使複雜的微創手術能夠以更高的可重複性和更精細的控制進行。

同時，混合手術環境的趨勢正在重塑資本配置的優先順序。醫療機構正在投資整合影像和介入的空間，以支持傳統的開放性手術和微創手術，並能夠在單一手術室內快速轉換通訊協定。影像設備必須能夠適應不同的手術流程，影像覆蓋區域必須針對手術室的人體工學進行最佳化，導航系統必須支援跨模態配準，以確保無縫的臨床交接。

服務和軟體產品正逐漸成為與硬體同等重要的差異化優勢。能夠提供強大影像處理、導航和工作流程管理功能以及硬體的供應商，更有能力建立長期的臨床和商業性合作關係。臨床醫生越來越期望透過軟體更新和模組化服務而非頻繁更換硬體來持續提升效能，這進一步強化了這種轉變。

供應鏈彈性也逐漸成為策略重點。地緣政治緊張局勢、關稅變化和零件短缺正在加速近岸外包、多方採購以及與長期供應商合作的進程。因此，那些能夠展現彈性製造地和可預測服務水準的公司正在贏得大型醫院系統和綜合醫療服務網路的關鍵信任。這些新興的市場動態正在重塑醫療保健整體技術的開發、檢驗、行銷和支援方式。

深入評估美國2025 年關稅改革如何改變影像引導治療提供者的籌資策略、購買行為和營運彈性

美國於2025年實施的政策調整對影像導引治療系統的供應鏈、採購慣例和投資計算產生了累積影響。關稅變化影響了進口影像模組和導航組件的總到岸成本，促使買家和供應商重新考慮籌資策略和總擁有成本分析。採購團隊的應對措施包括延長供應商資格認證週期並強調本地服務能力，以抵消與進口相關的潛在延誤和成本差異。

對於依賴全球零件採購的製造商來說，進口關稅的上漲增加了他們尋求多元化供應商和投資本地製造產能的獎勵。一些公司加快了在靠近關鍵終端用戶市場的組裝和零件製造方面的資本投資，而另一些公司則與頂級零件供應商協商簽訂了供應協議，以確保獲得優先分配。這些策略性因應措施並非立竿見影，需要仔細的資本規劃和產品藍圖的修改，以適應不同的製造公差和司法管轄區的監管核准。

臨床醫生和醫院管理人員也受到了間接影響。在資本核准週期易受價格波動影響的環境下，採購委員會推遲了某些不太緊急的升級，或採取了分階段採購的方式，優先考慮模組化擴展和服務契約，以平滑成本影響。同時，供應商透過更靈活的付款條件、延長保固期和配套服務產品調整了其商業模式，以減輕前期資本負擔並保持部署勢頭。

在營運方面，關稅壓力也影響了耗材和配件，凸顯了庫存管理和可預測供應的重要性。投資於庫存最佳化和替代供應商資格認證的醫療中心減少了流程中斷，並維持了服務水準。從策略角度來看，積極與供應商合作，共同設計區域供應安排或認證替代部件的醫療中心獲得了韌性優勢，使其能夠在政策驅動的成本環境中保持臨床吞吐量。

詳細的細分洞察揭示了推動差異化臨床和商業策略的模式、應用、最終用戶、產品、組件和治療類型維度

分割分析揭示了評估和應用影像引導治療系統的多個維度。就顯像模式而言，包括錐狀射束CT、CT、螢光透視、MRI和超音波，每種方式在空間解析度、軟組織對比度、放射線暴露和手術操作的實用性方面都有不同的權衡，這會影響臨床選擇和手術設計。根據應用，臨床需求涵蓋心血管、胃腸病學、神經病學、腫瘤學、整形外科和泌尿系統，每個專業都根據解剖複雜性和治療目標定義了各自的成像和導航要求。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將人工智慧驅動的影像分析整合到即時程式指導和決策支援中
  • 利用擴增實境疊加技術提高微創手術的精準度和視覺化效果
  • 結合先進影像診斷設備與機器人手術介入的混合手術室的開發
  • 針對照護現場手術進行最佳化的可攜式、緊湊型 C 臂成像系統的需求不斷成長
  • 雲端基礎的協作遠端手術規劃影像管理和分析平台的實現
  • 利用影像資料 3D 列印病患特定解剖模型用於術前手術演練的進展
  • 將輻射劑量減少技術整合到透視系統中，以提高病患安全標準
  • 磁振造影引導聚焦超音波系統的出現，使得神經系統疾病的非侵入性治療成為可能
  • 其可互通的開放平台架構簡化了醫學影像設備之間的資料共用。

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

8. 影像導引治療系統市場（依顯像模式）

  • 錐狀射束CT
  • CT
  • 透視
  • MRI
  • 超音波

9. 影像導引治療系統市場（依應用）

  • 心血管系統
  • 胃腸病學
  • 神經病學
  • 腫瘤學
  • 整形外科
  • 泌尿系統

第 10 章。影像導引治療系統市場（按最終用戶）

  • 門診手術中心
  • 醫院
  • 診斷影像中心
  • 專科診所

第 11 章影像導引治療系統市場（依產品）

  • 硬體
  • 服務
  • 軟體
    • 影像處理軟體
    • 導引軟體
    • 工作流程管理軟體

第 12 章：影像導引治療系統市場（按組件）

  • 配件
  • 耗材
  • 影像設備
  • 導引系統

第 13 章。影像導引治療系統市場（按治療類型）

  • 微創
    • 內視鏡檢查
    • 腹腔鏡
    • 機器人
  • 開放性手術

第 14 章：影像導引治療系統市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章。影像導引治療系統市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 16 章：影像導引治療系統市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • GE HealthCare Technologies Inc.
    • Siemens Healthineers AG
    • Medtronic plc
    • Koninklijke Philips NV
    • Stryker Corporation
    • Brainlab AG
    • Canon Medical Systems Corporation
    • Shimadzu Corporation
    • Olympus Corporation
    • Ziehm Imaging GmbH
Product Code: MRR-43127F7279B1

The Image-guided Therapy System Market is projected to grow by USD 8.54 billion at a CAGR of 7.49% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.79 billion
Estimated Year [2025] USD 5.14 billion
Forecast Year [2032] USD 8.54 billion
CAGR (%) 7.49%

Comprehensive introduction to the evolving image-guided therapy landscape where clinical precision, integrated platforms, and value-driven procurement redefine adoption patterns

The landscape of image-guided therapy systems is at an inflection point where clinical need, technological maturity, and payer and provider expectations are converging to demand faster, safer, and more cost-effective interventions. Hospitals and specialty facilities are moving beyond single-point investments in imaging hardware toward integrated solutions that combine advanced imaging modalities, real-time navigation, and software-driven workflow controls. This shift is driven by clinicians' demand for greater precision during procedures, administrators' emphasis on throughput and predictable outcomes, and patient expectations for minimally traumatic care pathways.

Clinically, the advantages of enhanced visualization and navigation are clear: reduced procedure times, minimized radiation exposure in certain modalities, and improved targeting accuracy for complex anatomies. Operationally, the push for hybrid suites and interoperable platforms is transforming procurement cycles, since capital planners now evaluate systems not only on image quality but also on software extensibility, service packages, and compatibility with existing OR ecosystem investments. As a result, stakeholders across clinical, purchasing, and IT functions are increasingly engaged in technology evaluation and adoption decisions.

Regulatory scrutiny and reimbursement dynamics are shaping the pace and nature of adoption. Regulators are placing greater emphasis on post-market evidence and real-world performance, especially for systems that incorporate machine learning or autonomous functions. Meanwhile, payers and health systems are increasingly focused on value-based outcomes, requiring vendors to demonstrate how new technologies reduce complications, shorten length of stay, or improve downstream care pathways. Taken together, these forces underscore the necessity for suppliers to present robust clinical evidence, clear operational benefits, and flexible commercial models to secure adoption across diverse care settings.

Analysis of the major transformative technological, operational, and supply chain shifts reshaping the future of image-guided therapy systems and clinical adoption

The image-guided therapy sector is experiencing transformative shifts driven by several concurrent technological and market dynamics. Advances in artificial intelligence and machine learning are improving image reconstruction, segmentation, and intra-procedural decision support, enabling clinicians to interpret multimodal imaging inputs with greater speed and consistency. Robotics and enhanced navigation systems are becoming more tightly integrated with imaging suites, enabling complex minimally invasive procedures to be performed with higher reproducibility and finer control.

Concurrently, the trend toward hybrid operating environments is reshaping capital allocation priorities. Institutions are investing in combined imaging and interventional spaces that support both traditional open surgery and minimally invasive approaches, enabling rapid protocol transitions within a single suite. This has profound implications for product design: imaging equipment must be adaptable to diverse procedural workflows, imaging footprints must be optimized for OR ergonomics, and navigation systems must support cross-modality registration to ensure seamless clinical handoffs.

Service and software offerings are gaining parity with hardware as sources of differentiation. Vendors that can deliver robust image processing, navigation, and workflow management capabilities alongside hardware options are better positioned to lock in long-term clinical and commercial relationships. This shift is reinforced by clinicians' growing expectations for continuous performance improvements delivered through software updates and modular services rather than through frequent hardware replacements.

Supply chain resiliency has also emerged as a strategic priority. Geopolitical tensions, tariff changes, and component scarcity have accelerated nearshoring, multi-sourcing, and longer-term supplier partnerships. As a result, companies that can demonstrate a resilient manufacturing footprint and predictable service levels are gaining an important trust advantage among large hospital systems and integrated delivery networks. These converging dynamics are reshaping how technologies are developed, validated, marketed, and supported across the care continuum.

Detailed assessment of how 2025 United States tariff changes have altered sourcing strategies, procurement behavior, and operational resilience for image-guided therapy providers

The policy adjustments enacted in the United States during 2025 introduced cumulative effects across supply chains, procurement practices, and investment calculus for image-guided therapy systems. Tariff changes influenced the total landed cost of imported imaging modules and navigation components, prompting buyers and suppliers to re-examine sourcing strategies and total cost of ownership analyses. Procurement teams responded by lengthening vendor qualification cycles and increasing emphasis on local service capabilities to offset potential import-related delays and cost volatility.

For manufacturers reliant on globally sourced parts, increased import duties amplified the incentive to diversify suppliers and invest in regional manufacturing capabilities. Some firms accelerated capital investments in assembly and component manufacturing closer to primary end-user markets, while others negotiated supply agreements with tier-one component suppliers to secure priority allocation. These strategic responses were not instantaneous; they required careful capital planning and revisions to product roadmaps to accommodate localized production tolerances and regulatory approvals in different jurisdictions.

Clinicians and hospital administrators felt indirect impacts as well. In environments where capital approval cycles are sensitive to price swings, procurement committees deferred certain non-urgent upgrades or adopted phased acquisition approaches, prioritizing modular expansions and service contracts that smoothed cost impacts. Simultaneously, vendors adjusted commercial models by offering more flexible payment terms, extended warranties, and bundled services to reduce initial capital burden and maintain adoption momentum.

Operationally, tariff-driven pressures also affected consumables and accessories, elevating the importance of inventory management and predictable supply. Facilities that invested in inventory optimization and alternative supplier qualification reduced procedural disruptions and maintained service levels. From a strategic perspective, organizations that proactively engaged with suppliers to co-design localized supply arrangements or to qualify alternative components gained a resilience advantage, enabling them to sustain clinical throughput while navigating the policy-induced cost environment.

In-depth segmentation insights revealing modality, application, end-user, product, component, and therapy-type dimensions that drive differentiated clinical and commercial strategies

Segmentation analysis highlights the multiple dimensions through which image-guided therapy systems are evaluated and adopted. Based on imaging modality, the landscape encompasses Cone Beam CT, CT, Fluoroscopy, MRI, and Ultrasound, each offering distinct trade-offs between spatial resolution, soft-tissue contrast, radiation exposure, and intra-procedural practicality, which in turn influences clinical choice and procedural design. Based on application, clinical demand spans Cardiovascular, Gastroenterology, Neurology, Oncology, Orthopedics, and Urology, with each specialty defining unique imaging and navigation requirements tied to anatomical complexity and therapeutic objective.

Based on end user, adoption dynamics differ markedly among Ambulatory Surgical Centers, Hospitals, Imaging Centers, and Specialty Clinics, where variations in case mix, capital budgets, staffing models, and throughput targets dictate different product and service preferences. Based on product, solutions are grouped into Hardware, Services, and Software; the Software component is further studied across Image Processing Software, Navigation Software, and Workflow Management Software, reflecting the central role software plays in enhancing clinical decision support, guiding instrumentation, and streamlining peri-procedural coordination.

Based on component, inventories and procurement strategies are shaped by Accessories, Consumables, Imaging Equipment, and Navigation Systems, each carrying different life cycles, regulatory pathways, and supply chain sensitivities that affect procurement cadence and total cost management. Based on therapy type, clinical workflows bifurcate into Minimally Invasive and Open Surgery; the Minimally Invasive category is further divided into Endoscopic, Laparoscopic, and Robotic approaches, each influencing device interfaces, imaging access, and navigation precision requirements. Together, these segmentation lenses provide a multidimensional framework for understanding buyer needs, tailoring clinical evidence generation, and designing differentiated commercial propositions for each stakeholder group.

Strategic regional perspectives demonstrating how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence procurement, adoption, and deployment of image-guided therapy systems

Regional dynamics continue to shape where and how investments in image-guided therapy systems are prioritized and deployed. In the Americas, investment momentum is concentrated in integrated delivery systems and large tertiary hospitals that value hybrid OR capabilities and comprehensive service arrangements, while a growing number of ambulatory surgical centers are selectively adopting minimally invasive solutions that offer rapid turnover and reduced recovery times. Health systems in this region are also increasingly focused on interoperability, data security, and outcomes measurement, requiring vendors to support complex IT integrations and post-deployment performance tracking.

In Europe, the Middle East & Africa region, adoption patterns vary significantly by country and health system maturity. Advanced European markets emphasize evidence generation, regulatory compliance, and cost-effectiveness, whereas several Middle Eastern markets are accelerating capital investments in flagship medical centers and specialty clinics, prioritizing high-end imaging suites and robotic integrations. In parts of Africa, constrained capital and workforce limitations favor solutions that are rugged, serviceable, and optimized for essential care delivery, creating opportunities for modular systems and innovative service models.

Asia-Pacific presents diverse trajectories driven by rapid investments in advanced care infrastructure in several markets and strong manufacturing capabilities in others. Large centers in the region are early adopters of robotic-assisted and image-integrated platforms, often leveraging local manufacturing partnerships to reduce cost and accelerate deployment. Across Asia-Pacific, growth is driven by demographic shifts, rising procedural volumes for oncology and cardiovascular interventions, and an increasing emphasis on reducing peri-procedural morbidity through minimally invasive approaches. Each regional cluster therefore requires tailored product configurations, service models, and clinical evidence strategies to align with local procurement norms and care delivery priorities.

Actionable corporate intelligence on how competitive moves, software-centric strategies, and service innovations are redefining leadership and partnership opportunities in image-guided therapy

Competitive dynamics in the image-guided therapy space are increasingly defined by end-to-end value propositions that combine imaging hardware, navigation platforms, and software-driven workflow orchestration. Leading companies are expanding portfolios through targeted partnerships, acquisitions, and co-development agreements that accelerate integration between imaging modalities and navigation suites. These moves are intended to reduce clinical friction and provide clearer upgrade paths for health systems seeking interoperable, scalable solutions.

A pronounced shift toward software-defined differentiation is reshaping product roadmaps. Firms investing in image processing algorithms, enhanced visualization, and intuitive navigation interfaces are improving clinician acceptance and reducing training burdens. Service offerings-ranging from preventative maintenance and remote diagnostics to embedded procedural coaching and outcome analytics-are becoming core revenue drivers and customer retention mechanisms. Organizations that excel at delivering predictable uptime and clinically meaningful analytics are building stronger long-term contracts and deeper clinical partnerships.

Strategic players are also addressing reimbursement and evidence gaps by sponsoring clinical studies, real-world evidence programs, and collaborative registries that document outcomes across procedural settings. This evidence not only supports clinical adoption but also strengthens value narratives during contracting negotiations with payers and integrated delivery networks. Finally, innovation in consumables and accessory design-focused on disposability, sterility workflows, and cost-effectiveness-remains a fast-moving front where relatively smaller players can achieve rapid market traction through targeted clinical use cases.

Practical, high-impact recommendations for product, clinical evidence, supply chain, and commercial strategies that executives can implement to accelerate adoption and long-term growth

Industry leaders should prioritize a set of coordinated actions to capture clinical and commercial advantage in image-guided therapy systems. First, align product roadmaps to deliver modular interoperability across imaging modalities and navigation platforms, enabling customers to scale capabilities without full-system replacement. Designing products for incremental upgrades reduces procurement friction and broadens addressable use cases across hospitals, ambulatory centers, and specialty clinics.

Second, invest in clinical evidence programs that tie procedural improvements to concrete patient outcomes and operational metrics. Collaborations with high-volume clinical centers, registries, and specialty societies can accelerate the evidence generation process and strengthen reimbursement conversations. Third, expand services and software subscriptions to shift commercial models toward predictable recurring revenue while delivering tangible operational improvements for care providers, including reduced downtime, streamlined workflows, and data-driven clinical decision support.

Fourth, strengthen supply chain resilience through regional manufacturing, dual sourcing, and strategic inventory partnerships to mitigate tariff impacts and component scarcity. Proactively sharing contingency plans with large customers builds trust and reduces the risk of contract disruptions. Fifth, tailor regional go-to-market strategies that reflect local procurement behaviors and clinical practice patterns; a one-size-fits-all approach will undermine adoption in diverse healthcare systems. Finally, prioritize user-centered design and clinician training programs to accelerate proficiency and reduce the learning curve, which in turn accelerates utilization and demonstrates faster return on procedural efficiency.

Robust and transparent research methodology combining primary clinician and procurement interviews with secondary validation and multi-source triangulation to ensure actionable findings

The research methodology underpinning these insights combined structured primary research with comprehensive secondary validation and rigorous triangulation. Primary inputs included in-depth interviews with interventional clinicians across specialties such as cardiology, neurology, oncology, and orthopedics, procurement leaders from hospitals and ambulatory surgical centers, and technical managers responsible for imaging and navigation system deployments. These conversations provided firsthand perspectives on clinical requirements, procurement constraints, and operational performance considerations.

Secondary research synthesized regulatory guidances, clinical literature, technology whitepapers, and publicly available product documentation to contextualize primary inputs and verify technology capabilities. Data triangulation was applied to reconcile variations across sources and to identify consensus views on adoption drivers and barriers. Where applicable, scenario analysis was used to explore the implications of policy shifts, component availability, and reimbursement changes on procurement behavior and deployment timelines.

Quality control procedures included cross-validation of respondent inputs, internal peer reviews, and expert panel discussions to ensure that conclusions were robust and actionable. Segmentation frameworks were mapped against clinical workflows and procurement archetypes to ensure relevance for both strategic planning and tactical commercialization. The resulting methodology supports reproducible insights that can be applied to tailored assessments for product development, go-to-market planning, and investment evaluation.

Concise conclusion emphasizing the imperative for integrated technical, clinical, and commercial strategies to realize the promise of image-guided therapy across care settings

The trajectory for image-guided therapy systems is clear: clinical demand for precision, operational efficiency, and patient-centered outcomes will continue to drive adoption of integrated imaging, navigation, and software platforms. Successful suppliers will be those that can combine clinical evidence, flexible commercial models, resilient supply chains, and user-centric designs to lower the barriers to adoption across diverse care settings. The interplay of technological innovation and shifting procurement behaviors requires agile strategies that balance immediate operational needs with long-term platform development.

Tariff-related pressures and regional investment patterns underscore the importance of localized strategies and supplier diversification. Companies that proactively adapt manufacturing footprints, offer modular upgrade pathways, and align clinical evidence efforts with payer and provider priorities will be better positioned to sustain growth and secure meaningful clinical partnerships. Ultimately, the most successful organizations will translate technical differentiation into measurable clinical and economic value, enabling providers to deliver safer, more efficient interventions while strengthening their own commercial and strategic positions in a rapidly evolving healthcare landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven image analysis into real-time procedural guidance and decision support
  • 5.2. Adoption of augmented reality overlays to enhance precision and visualization in minimally invasive surgeries
  • 5.3. Development of hybrid operating rooms combining advanced imaging modalities with robotic surgical intervention
  • 5.4. Rising demand for portable compact C-arm imaging systems optimized for point-of-care interventional procedures
  • 5.5. Implementation of cloud-based image management and analytics platforms for collaborative remote procedural planning
  • 5.6. Advances in 3D printing of patient-specific anatomical models from imaging data for preoperative surgical rehearsal
  • 5.7. Integration of radiation dose reduction technologies in fluoroscopic systems to improve patient safety standards
  • 5.8. Emergence of MR-guided focused ultrasound systems enabling non-invasive treatment of neurological disorders
  • 5.9. Adoption of interoperable open-platform architectures to streamline data sharing across medical imaging devices

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Image-guided Therapy System Market, by Imaging Modality

  • 8.1. Cone Beam Ct
  • 8.2. Ct
  • 8.3. Fluoroscopy
  • 8.4. Mri
  • 8.5. Ultrasound

9. Image-guided Therapy System Market, by Application

  • 9.1. Cardiovascular
  • 9.2. Gastroenterology
  • 9.3. Neurology
  • 9.4. Oncology
  • 9.5. Orthopedics
  • 9.6. Urology

10. Image-guided Therapy System Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Imaging Centers
  • 10.4. Specialty Clinics

11. Image-guided Therapy System Market, by Product

  • 11.1. Hardware
  • 11.2. Services
  • 11.3. Software
    • 11.3.1. Image Processing Software
    • 11.3.2. Navigation Software
    • 11.3.3. Workflow Management Software

12. Image-guided Therapy System Market, by Component

  • 12.1. Accessories
  • 12.2. Consumables
  • 12.3. Imaging Equipment
  • 12.4. Navigation System

13. Image-guided Therapy System Market, by Therapy Type

  • 13.1. Minimally Invasive
    • 13.1.1. Endoscopic
    • 13.1.2. Laparoscopic
    • 13.1.3. Robotic
  • 13.2. Open Surgery

14. Image-guided Therapy System Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Image-guided Therapy System Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Image-guided Therapy System Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. GE HealthCare Technologies Inc.
    • 17.3.2. Siemens Healthineers AG
    • 17.3.3. Medtronic plc
    • 17.3.4. Koninklijke Philips N.V.
    • 17.3.5. Stryker Corporation
    • 17.3.6. Brainlab AG
    • 17.3.7. Canon Medical Systems Corporation
    • 17.3.8. Shimadzu Corporation
    • 17.3.9. Olympus Corporation
    • 17.3.10. Ziehm Imaging GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. IMAGE-GUIDED THERAPY SYSTEM MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. IMAGE-GUIDED THERAPY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IMAGE-GUIDED THERAPY SYSTEM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONE BEAM CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONE BEAM CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONE BEAM CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONE BEAM CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONE BEAM CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONE BEAM CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY FLUOROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY FLUOROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY FLUOROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY FLUOROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY FLUOROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY FLUOROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY UROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY UROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY UROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY UROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY UROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY UROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGE PROCESSING SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGE PROCESSING SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGE PROCESSING SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGE PROCESSING SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGE PROCESSING SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGE PROCESSING SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ROBOTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ROBOTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ROBOTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ROBOTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ROBOTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ROBOTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY OPEN SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MI